86 related articles for article (PubMed ID: 12490109)
1. A preliminary clinical application of sICAM-1 RIA in three kinds of thyroid disease.
Lu M; Fang P; Zhang Z; He H; Gao S; Hou B; Zheng R; Xiao Q; Yang L
Chin Med J (Engl); 2002 Oct; 115(10):1552-5. PubMed ID: 12490109
[TBL] [Abstract][Full Text] [Related]
2. Increased serum neopterin levels in patients with Graves' disease.
Wagner R; Hayatghebi S; Rosenkranz M; Reinwein D
Exp Clin Endocrinol; 1993; 101(4):249-54. PubMed ID: 8307114
[TBL] [Abstract][Full Text] [Related]
3. Influence of thyroxine on serum soluble interleukin-2 receptor alpha levels in thyroid disorders.
Zwirska-Korczala K; Berdowska A; Jochem J; Sitkiewicz A; Birkner E; Polaniak R; Jedrzejowska-Szypułka H; Korzonek-Szlacheta I
J Clin Pharm Ther; 2004 Apr; 29(2):151-6. PubMed ID: 15068404
[TBL] [Abstract][Full Text] [Related]
4. Soluble intercellular adhesion molecule-1 (sICAM-1) in Graves' disease.
Balázs C; Kiss E
Acta Microbiol Immunol Hung; 1994; 41(4):451-6. PubMed ID: 7866729
[TBL] [Abstract][Full Text] [Related]
5. Soluble Fas, Fas ligand and Bcl-2 in autoimmune thyroid diseases: relation to humoral immune response markers.
Myśliwiec J; Okota M; Nikołajuk A; Górska M
Adv Med Sci; 2006; 51():119-22. PubMed ID: 17357290
[TBL] [Abstract][Full Text] [Related]
6. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
[TBL] [Abstract][Full Text] [Related]
7. Th1 and Th2 serum cytokine profiles characterize patients with Hashimoto's thyroiditis (Th1) and Graves' disease (Th2).
Phenekos C; Vryonidou A; Gritzapis AD; Baxevanis CN; Goula M; Papamichail M
Neuroimmunomodulation; 2004; 11(4):209-13. PubMed ID: 15249726
[TBL] [Abstract][Full Text] [Related]
8. Circulating chemokines in patients with autoimmune thyroid diseases.
Domberg J; Liu C; Papewalis C; Pfleger C; Xu K; Willenberg HS; Hermsen D; Scherbaum WA; Schloot NC; Schott M
Horm Metab Res; 2008 Jun; 40(6):416-21. PubMed ID: 18415893
[TBL] [Abstract][Full Text] [Related]
9. Endothelin-1 levels in patients with disorders of the thyroid gland.
Tilly N; Schneider JG; Leidig-Bruckner G; Sommer U; Kasperk C
Exp Clin Endocrinol Diabetes; 2003 Apr; 111(2):80-4. PubMed ID: 12746758
[TBL] [Abstract][Full Text] [Related]
10. [Impact of serum thyroglobulin concentration in the diagnosis of benign and malignant thyroid diseases].
Rink T; Dembowski W; Schroth HJ; Klinger K
Nuklearmedizin; 2000 Aug; 39(5):133-8. PubMed ID: 10984889
[TBL] [Abstract][Full Text] [Related]
11. Serum CD40/CD40L system in Graves' disease and Hashimoto's thyroiditis related to soluble Fas, FasL and humoral markers of autoimmune response.
Mysliwiec J; Oklota M; Nikolajuk A; Waligorski D; Gorska M
Immunol Invest; 2007; 36(3):247-57. PubMed ID: 17558708
[TBL] [Abstract][Full Text] [Related]
12. Decrease of peripheral large granular lymphocytes in Graves' disease.
Iwatani Y; Amino N; Kabutomori O; Mori H; Tamaki H; Motoi S; Izumiguchi Y; Miyai K
Clin Exp Immunol; 1984 Jan; 55(1):239-44. PubMed ID: 6546360
[TBL] [Abstract][Full Text] [Related]
13. [Serum levels of adhesion molecules (sICAM-1, sVCAM-1 and sP-selectin) in children and adolescents with thyroid diseases].
Bossowski A; Urban M; Citko A; Sobotko J; Bossowska A
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2000; 6(2):79-92. PubMed ID: 12818068
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Serio M; Miccoli P
Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
[TBL] [Abstract][Full Text] [Related]
15. [Change of serum soluble intercellular adhesion molecule and basic fibroblast growth factor in patients with acute cerebral infarction and its clinical significance].
Song S; Zheng X; Wen S; Huang J; Ding D
Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(21):1447-9. PubMed ID: 12509902
[TBL] [Abstract][Full Text] [Related]
16. Soluble intercellular adhesion molecule-1 (sICAM-1) concentrations in Graves' disease patients followed up for development of ophthalmopathy.
De Bellis A; Di Martino S; Fiordelisi F; Muccitelli VI; Sinisi AA; Abbate GF; Gargano D; Bellastella A; Bizzarro A
J Clin Endocrinol Metab; 1998 Apr; 83(4):1222-5. PubMed ID: 9543145
[TBL] [Abstract][Full Text] [Related]
17. Decreased nerve growth factor levels in hyperthyroid Graves' ophthalmopathy highlighting the role of neuroprotective factor in autoimmune thyroid diseases.
Molnár I; Bokk A
Cytokine; 2006 Aug; 35(3-4):109-14. PubMed ID: 17008110
[TBL] [Abstract][Full Text] [Related]
18. Intercellular adhesion molecule-1 (ICAM-1) in the sera of patients with Graves' disease: correlation with disease activity and treatment status.
Fukazawa H; Yoshida K; Kaise N; Kiso Y; Sayama N; Mori K; Kikuchi K; Aizawa Y; Rikimaru A; Abe K
Thyroid; 1995 Oct; 5(5):373-7. PubMed ID: 8563475
[TBL] [Abstract][Full Text] [Related]
19. Behavior of soluble intercellular adhesion molecule-1 and endothelial-leukocyte adhesion molecule-1 concentrations in patients with Graves' disease with or without ophthalmopathy and in patients with toxic adenoma.
De Bellis A; Bizzarro A; Gattoni A; Romano C; Di Martino S; Sinisi AA; Abbadessa S; Bellastella A
J Clin Endocrinol Metab; 1995 Jul; 80(7):2118-21. PubMed ID: 7541801
[TBL] [Abstract][Full Text] [Related]
20. Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves' disease and Hashimoto's thyroiditis.
Iitaka M; Miura S; Yamanaka K; Kawasaki S; Kitahama S; Kawakami Y; Kakinuma S; Oosuga I; Wada S; Katayama S
J Clin Endocrinol Metab; 1998 Nov; 83(11):3908-12. PubMed ID: 9814467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
